Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 927.57M | 967.26M | 1.39B | 930.67M | 891.39M |
Gross Profit | 439.56M | 451.13M | 603.05M | 485.77M | 460.98M |
EBITDA | -115.25M | 126.38M | 150.72M | -1.39B | -909.23M |
Net Income | -54.59M | 41.29M | 75.46M | -1.45B | -974.02M |
Balance Sheet | |||||
Total Assets | 3.77B | 3.67B | 3.73B | 3.19B | 1.58B |
Cash, Cash Equivalents and Short-Term Investments | 1.66B | 2.03B | 2.00B | 2.15B | 956.29M |
Total Debt | 398.36M | 194.29M | 199.86M | 18.19M | 85.39M |
Total Liabilities | 950.51M | 774.23M | 871.62M | 464.15M | 3.41B |
Stockholders Equity | 2.78B | 2.87B | 2.83B | 2.72B | -1.84B |
Cash Flow | |||||
Free Cash Flow | -179.57M | -189.65M | -102.90M | -220.23M | 46.68M |
Operating Cash Flow | -44.12M | -14.78M | 21.41M | 68.03M | 73.46M |
Investing Cash Flow | -1.21B | 854.92M | -1.35B | -666.06M | -121.96M |
Financing Cash Flow | 144.63M | -82.83M | 97.64M | 1.59B | 851.92M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | HK$675.48M | 8.18 | 5.33% | 7.92% | 0.47% | 50.46% | |
66 Neutral | HK$1.64B | 5.64 | 20.47% | 4.37% | -3.56% | -17.45% | |
64 Neutral | HK$390.48M | 7.53 | -8.40% | 2.76% | -21.31% | -149.92% | |
54 Neutral | HK$1.69B | ― | -4.66% | 0.47% | -0.55% | 45.36% | |
51 Neutral | $7.95B | -0.38 | -43.43% | 2.22% | 22.30% | -1.83% | |
48 Neutral | HK$949.39M | 6.53 | 30.40% | ― | 2.30% | ― | |
46 Neutral | HK$1.55B | 130.77 | -3.59% | 1.60% | -4.09% | -1242.31% |
Kindstar Globalgene Technology, Inc. reported a decrease in revenue and a significant net loss for the first half of 2025, attributed to external market pressures, increased operating costs, and losses from recent acquisitions. The company’s gross profit margin also declined due to these factors, impacting its financial performance and highlighting the challenges faced in maintaining profitability amidst a competitive market environment.
The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.
Kindstar Globalgene Technology, Inc. has announced a change in its company secretary, authorized representative, and process agent roles. Ms. Lee Mei Yi has resigned from these positions, effective August 29, 2025, and will be succeeded by Ms. Chai Haijie as the sole company secretary and Mr. Tu Zanbing as the authorized representative. Additionally, Ms. Pun Ka Ying will replace Ms. Lee as the process agent. The company expressed gratitude for Ms. Lee’s contributions during her tenure.
The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.
Kindstar Globalgene Technology, Inc. has issued a profit warning, anticipating a net loss of RMB30 million to RMB35 million for the first half of 2025, compared to a net profit of RMB10.5 million in the same period of 2024. The losses are attributed to a decrease in revenue, losses from fair value changes on funds, expected credit losses related to COVID-19, and expenses from recent acquisitions. Despite these challenges, the company’s core business remains stable.
The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.
Kindstar Globalgene Technology, Inc. has announced an upcoming board meeting scheduled for August 28, 2025, to discuss and approve the company’s consolidated interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.